|Bid||0.4070 x 2200|
|Ask||0.4432 x 1400|
|Day's Range||0.4000 - 0.4439|
|52 Week Range||0.3200 - 11.7800|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
NEW YORK, NY / ACCESSWIRE / July 19, 2018 / Texas Instruments Incorporated closed down modestly on Wednesday. The company's CEO Brian Crutcher recently resigned for violating conduct and in his place, former CEO Rich Templeton has taken his position. Shares of Precipio saw big gains after announcing preliminary second quarter results.
Specialty cancer diagnostics company Precipio, Inc. (PRPO), today announced preliminary second quarter results representing continued triple digit YoY growth. Quarter over quarter sequential growth was 14% which, at a compounded run rate of circa 70% annually currently represents early stage growth generated from pathology services. In Q4-2017 and in Q1-2018, YoY revenue growth was 199% and 187% respectively, showing continued triple-digit YoY growth.
Specialty diagnostics company Precipio, Inc. (PRPO), announced today an agreement with Israel-based artificial intelligence pathology platform company Nucleai who specializes in applying Machine Learning and Machine Vision algorithms to pathology domain. Nucleai’s experienced team has adapted artificial intelligence technology previously used for satellite image analysis to the detection of cancer using biopsy image analysis to distinguish between abnormal, potentially malignant cells and normal cells.
Stock Research Monitor: PKI, PRAH, and PRPO LONDON, UK / ACCESSWIRE / June 26, 2018/ If you want a free Stock Review on DGX sign up now at www.wallstequities.com/registration . On Monday, benchmark US ...
The eight ICP trials are underway with three reference laboratories, one hospital laboratory, two with a large contract research organization (CRO) and two diagnostic equipment companies. The 12 agreements for the upcoming ICP kit trials consist of two reference labs, two CROs, seven hospital labs, and a pharma company.
Specialty diagnostics company Precipio, Inc. (PRPO), announced today that the Company’s 2018 Annual Meeting of Shareholders, originally scheduled for 9:30 a.m., Eastern Standard Time on Friday, June 15th, 2018 at the offices of the Company at 4 Science Park, New Haven, CT 06511 was adjourned due to the fact that the percentage of shareholders participating in the proxy vote totaled approximately 45%, thereby not reaching the quorum of 50% required to conduct business and approve the measures. The meeting is rescheduled for July 6th, 2018 at 10:00 a.m. Eastern Standard Time at the offices of the Company. Company management noted that of the votes received, all measures requiring a for/against vote received a “For” vote of over 95%.
Specialty diagnostics company Precipio, Inc. (PRPO), today reminded its shareholders to vote on proposals 1-6 in accordance with the recommendations of the Board, as set out in the proxy material previously mailed to the shareholders on or about June 5, 2018, for the Company's upcoming Annual General Meeting which will be held TOMORROW, June 15, 2018 at 9:30am Eastern Standard Time at the Company’s office in New Haven. Use the Internet to transmit your voting instructions and for electronic delivery of information. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form.
NEW HAVEN, Conn., June 12, 2018-- Specialty diagnostics company Precipio, Inc., today reminded its shareholders to vote on proposals 1-6 in accordance with the recommendations of the Board, as set out ...
Specialty cancer diagnostics company Precipio, Inc. (PRPO), today announced the award of US patent No. 9,957,556 entitled FULL COLD-PCR ENRICHMENT WITH REFERENCE BLOCKING SEQUENCE, to Harvard-affiliated Dana-Farber Cancer Institute, the licensor of Precipio’s ICE-COLD PCR DNA enrichment platform, and to Precipio’s scientific advisory board member Dr. Gerassimos (Mike) Makrigiorgos. The agreement between Precipio and Dana-Farber Cancer Institute provides for the exclusive, worldwide license rights for ICE-COLD PCR and related technologies. While previous patents issued on ICE COLD-PCR related to process methods, the new patent protects the use and application of kits containing reagents essential to performing ICE-COLD PCR.
In this analysis, my focus will be on developing a perspective on Precipio Inc’s (NASDAQ:PRPO) latest ownership structure, a less discussed, but important factor. A company’s ownership structure is oftenRead More...
Specialty cancer diagnostics company Precipio, Inc. (PRPO), today announced its entry into an agreement with Italy-based biotechnology products distributor Euroclone Diagnostica S.r.l (Euroclone) to sell Precipio’s ICE COLD-PCR™ (ICP) DNA enrichment products for use with liquid biopsies. The agreement provides for Euroclone’s exclusive representation and distribution of Precipio’s ICP products in Italy and non-exclusive representation for the rest of Europe.
Specialty cancer diagnostics company Precipio, Inc. (PRPO), today announced accelerating sales of its Pathology services in the month of April, indicating anticipated sequential double digit quarterly sales growth. Of the numerous key performance indicators (KPI) we track, two of the most important are average number of cases per day, and total case volume, both of which increased in April at a quarterly run rate of approximately ~150% over Q1.
Ahead of today's trading session, WallStEquities.com scans four Medical Laboratories and Research stocks, particularly: PerkinElmer Inc. (NYSE: PKI), Precipio Inc. (NASDAQ: PRPO), Syneos Health Inc. (NASDAQ: SYNH), and Thermo Fisher Scientific Inc. (NYSE: TMO). Medical laboratories are independent, commercial enterprises that provide information to the health care professionals about the severity, onset, and reason of patients' physical ailments.
Specialty diagnostics company Precipio, Inc. (PRPO), today announced the launch of two additional ICEme™ kits using its proprietary ICE-COLD PCR™ liquid biopsy technology. The new RUO kits enable the detection of mutations in KRAS Exons 2 & 3, which include important predictive and prognostic biomarkers, and are available on both qPCR and Sanger molecular diagnostic platforms. The 5-year survival rate for stage I pancreatic cancer is ~14%, a number that drops to 3% for stage III patients, and 1% for stage IV patients1.
NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Shares of Precipio and Teva were gaining full speed on Monday. Precipio shares exploded after the company announced a substantial preliminary unaudited first ...
Specialty diagnostics company Precipio, Inc. (PRPO), announces preliminary, unaudited 1st quarter 2018 revenues of approximately $712,000, representing a 286% increase from the same quarter in the prior year. “With the completion of our sales reorganization and increasing business stabilization, we are focused on aggressively capturing market share with our disruptive diagnostic products and services,” commented Ilan Danieli, CEO.
Specialty diagnostics company Precipio, Inc. (PRPO), provides details of its previously announced upcoming shareholder conference call scheduled for Monday April 30, 2018 at 4:30PM EST, where management will provide an extensive strategic business update and will respond to questions submitted in advance via email. International callers should call 1-412-317-6789. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine and Harvard’s Dana-Farber Cancer Institute, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care.
Specialty diagnostics company Precipio, Inc. (PRPO), announced today that it entered into a convertible debt financing facility of up to $3M, to be drawn down at the option of the company (See the company’s Form 8-K filed on April 23rd, 2018). New and existing investors participated in the financing, to be used for working capital, including for the potential growth initiatives described below. Despite a tight top talent market, Precipio has recently hired an experienced VP of Sales along with seasoned sales representatives that have already begun to increase revenues.
While small-cap stocks, such as Precipio Inc (NASDAQ:PRPO) with its market cap of US$5.18M, are popular for their explosive growth, investors should also be aware of their balance sheet toRead More...